Lexicon Pharmaceuticals Inc (LXRX) Q1 2025 Earnings Call Highlights: Strategic Partnerships and ...
Release Date: May 13, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) announced an exclusive license agreement with Novo Nordisk for LX 9,851, potentially generating up to $1 billion in milestone payments and tiered royalties.
The company identified a well-tolerated dose for Pillovapidin in its Phase 2B study, paving the way for Phase 3 trials.
Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) successfully reduced operating costs and improved its balance sheet by utilizing upfront payments to reduce debt.
The Sonata HCM study for sotocoflozin is progressing well, with all Phase 3 sites expected to be operational by Q3 2025.
The company ended Q1 2025 with $194.8 million in cash and short-term investments, providing a strong financial position for future developments.
Net loss for Q1 2025 was $25.3 million, although reduced from the previous year, it still indicates financial challenges.
Research and development expenses increased to $15.3 million, reflecting higher costs associated with late-stage development programs.
Revenue from MPEFA sales was limited, with minimal promotional activity impacting potential growth.
The company faces significant competition in the HCM market, with other companies also targeting this space.
There is uncertainty regarding the FDA's feedback on the Phase 3 trial designs for Pillovapidin, which could impact future development timelines.
Warning! GuruFocus has detected 3 Warning Signs with LXRX.
Q: Can you discuss the intended trial designs for the pain program and whether it makes sense to conduct three studies instead of two? A: Craig Granowitz, Chief Medical Officer, explained that the plan is to run two parallel trials with similar designs. One trial will be US-only, and the other will be worldwide, including US and non-US sites. Each trial will have about 300-350 patients per arm, testing a 10 mg dose versus placebo. They believe the clinical signal is robust and do not see the need for a third trial unless advised by the FDA.
Q: Assuming the phase 2 goes well, when would the phase 3 pain data sets be available, and what additional studies are needed for an NDA filing? A: Craig Granowitz mentioned that addiction liability studies, likely in animal models, and additional metabolism studies are necessary. They are also validating renal clearance levels. Long-term CARC studies and preclinical trials are planned. They are confident in their manufacturing process and expect FDA feedback to guide any additional requirements.
Q: How are the IND enabling studies for LX 9,851 progressing, and how involved is Novo Nordisk in this stage? A: Mike Eton, CEO, stated that the IND enabling studies are on track to finish this year. Novo Nordisk is highly engaged and collaborative, with direct access to data outputs. The studies are expected to conclude this year, after which Novo will submit the IND.
Q: With recent updates in the HCM space, including the failed Odyssey trial, how does this affect your strategy for Soda in non-obstructive HCM? A: Mike Eton expressed confidence in Soda's potential for both obstructive and non-obstructive HCM. The Sonata trial is powered to see effects in both groups, and they do not plan to increase sample sizes. The trial design allows for rapid enrollment, and they believe Soda can be a significant treatment option.
Q: Regarding the Sonata study, how are you ensuring a homogeneous population for non-obstructive HCM, and what are the inclusion criteria? A: Craig Granowitz explained that the trial focuses on symptomatic disease, reflecting diastolic dysfunction, a key aspect of HCM. They are confident in their HEFA results and believe non-obstructive HCM is a subset of HEFA. The trial design aims to capture a broad patient population, and they have confidence in the efficacy of Soda in this group.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
28 minutes ago
- Business Upturn
Tata Tech shares lower after large block deal of 2.1% equity today
By Aditya Bhagchandani Published on June 4, 2025, 09:27 IST Shares of Tata Technologies Ltd traded lower on Tuesday after a large block deal involving a 2.1% equity stake, valued at approximately ₹634 crore, hit the markets. The deal was executed at a floor price of ₹744.5 per share, representing a 3% discount to Tata Technologies' closing price of ₹767.5 on June 3. As per media reports, the stake was sold by US-based private equity firm TPG through its arm TPG Rise Climate SF Pte Ltd. The transaction is being facilitated by BofA Securities and is reportedly structured as a 'clean-up trade,' indicating a strategic exit by the investor. Tata Technologies' stock opened on a weaker note and was trading at ₹762.80, down 0.61% from the previous close. The day's trading range was ₹754.20 to ₹765.50. The company's market cap stood at ₹308.26 billion, with a trailing P/E ratio of 45.67 and dividend yield of 1.10%. TPG's partial exit comes after a strong performance by Tata Tech stock, which has gained over 15% in the past month. Neither TPG nor BofA Securities has issued an official statement on the deal as of now. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Yahoo
40 minutes ago
- Yahoo
Alarming map surrounding Australia highlights growing danger to $3.8 billion industry
Populations of whales that survived decades of hunting now face new threats as they migrate from Antarctica to Australia. On Wednesday, World Wide Fund for Nature (WWF) launched an interactive map of the world highlighting where the routes of 1,400 whales collide with threats from ships, noise, fossil fuel projects, pollution, fishing and climate change. Whales are critical to ocean health and play an important role in tourism, creating US$2.1 billion (A$3.8 billion) in global revenue and supporting 13,000 jobs. It's hoped the publicly accessible platform will help stop more species of whale from becoming extinct by pinpointing where the dangers occur. And there are plans to gradually add more data from rarely seen species like beaked whales, of which very little is known. Of particular concern to WWF is the North Atlantic right whale which continues to be killed by ships and fishing gear entanglement, and with fewer than 70 breeding females left, the species is showing no signs of recovery. Southern right whales that we see in Australia are also of concern because their numbers have cryptically stagnated at a level far below pre-whaling levels. Related: Carloads of Aussies flock to water's edge for whale migration ritual Chris Johnson, the global lead for WWF's Protecting Whales and Dolphins Initiative, said the project is designed to be another 'building block' as researchers try to fill gaps in our knowledge about the oceans. 'Whales are these ocean giants that we absolutely love, particularly in Australia, and we still know so little about their migratory patterns,' he told Yahoo News from Melbourne. 'I study sperm whales and there's very little satellite tagging of them, and we don't do a lot of research offshore. We're still discovering new beaked whale species and they're the size of elephants.' More than 50 global research groups were involved in the map's creation. As more data is added to the platform, researchers will be able to gain new insights into the cumulative impact of multiple man-made threats on whales. 📸 Incredible whale spotted just metres from shore thrills tourists 😳 Disturbing photos emerge of famous orcas linked to 'dangerous myth' 🏝️ Tourists stunned by whale encounter off the Aussie coast For instance, the Queensland government announced last week it would be investing $88 million to expand its shark control program, which will include nets known to frequently entangle whale mothers and calves. An average of six whale entanglements a year may not seem like many, but it's adding to a massive global problem. Johnson said the announcement was 'disappointing' because there are modern alternatives to problematic nets. 'It's concerning because bycatch is probably the biggest issue for cetaceans worldwide. Around 300,000 a year die from entanglement and that's an issue from 25 years ago, so the problem is now probably much bigger,' he said. Today, seven of the world's 14 great whale species are threatened with extinction, and their migration routes are critical to their breeding and feeding. Shipping, fishing and gas and oil drilling have been important to industrialisation and the advancement of human interests. Transporting new phones and electric vehicles across the globe, and catching more fish for oil supplements, will continue to enrich our lives, but as more species are lost, the planet becomes less complex and arguably less interesting. By highlighting where the biggest problem areas are, companies will be empowered to make changes to lessen their impact on whales. Johnson said there are examples of this already occurring. In the North Atlantic, companies are altering their fishing methods, with some no longer using rope so whales aren't entangled. In Greece, shipping lanes have been modified to reduce the chances of collisions, and similar changes are being made in Asia. 'Off Sri Lanka, there's a big habitat for blue whales in the northern Indian Ocean. It's one of the busiest shipping lanes on Earth,' he said. 'But research has shown if you move the shipping lane 15 nautical miles further south, it'll reduce ship strikes.' While the government has been slow to respond, shipping companies themselves have been altering their routes in order to reduce the number of strikes. If all of them agree to reroute, the risk of collision would be reduced by 95 per cent. Love Australia's weird and wonderful environment? 🐊🦘😳 Get our new newsletter showcasing the week's best stories.
Yahoo
an hour ago
- Yahoo
Merus N.V. Announces Pricing of Public Offering of Common Shares
UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) ('Merus', the 'Company,' 'we' and 'our'), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced the pricing of an underwritten public offering of 5,263,158 common shares, at a public offering price of $57.00 per share (the 'Offer Shares'). Merus also granted the underwriters a 30-day option to purchase up to an additional 789,473 common shares (the 'Option Shares' and together with the Offer Shares, the 'Shares'). The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses and excluding the underwriters' option to purchase the Option Shares, are expected to be approximately $300.0 million. All of the shares in the offering are to be sold by Merus. The offering is expected to close on or about June 5, 2025, subject to customary closing conditions. Merus currently intends to use the net proceeds from the offering, together with its existing cash, cash equivalents and marketable securities, to advance the clinical development of its product candidates, for preclinical research and technology development, and for working capital and general corporate purposes. Jefferies, BofA Securities, Leerink Partners, Guggenheim Securities, Truist Securities, and LifeSci Capital are acting as joint book-running managers for the offering. Van Lanschot Kempen is acting as lead manager for the offering. The offering is being made pursuant to a shelf registration statement on Form S-3 that was filed with the Securities and Exchange Commission ('SEC') on February 28, 2024 and was effective upon filing. The offering will be made only by means of a written prospectus and prospectus supplement that form a part of the registration statement, which, for the avoidance of doubt, will not constitute a 'prospectus' for the purposes of (i) Regulation (EU) 2017/1129 (the 'Prospectus Regulation') and has not been reviewed by any competent authority in any member state in the European Economic Area (the 'EEA') and (ii) the Prospectus Regulation as it forms part of domestic law in the United Kingdom by virtue of the European Union (Withdrawal) Act 2018 (the 'UK Prospectus Regulation') and has not been reviewed by the Financial Conduct Authority in the United Kingdom. A preliminary prospectus supplement and accompanying prospectus relating to the offering was filed with the SEC on June 3, 2025, and a final prospectus supplement will be filed with the SEC and will be available on the SEC's website at Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained, when available, from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@ BofA Securities NC1-0220-02-25, Attention: Prospectus Department, 201 North Tryon Street, Charlotte, NC 28255‐0001, or by email at Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at (800) 808-7525 ext. 6105, or by email at syndicate@ Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@ or Truist Securities, Inc., Attention: Equity Capital Markets, 3333 Peachtree Road NE, 9th Floor, Atlanta, GA 30326 at (800) 685-4786 or by email to This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. This press release is an advertisement and not a prospectus within the meaning of either the Prospectus Regulation or the UK Prospectus Regulation. EEA: In relation to each member state of the EEA (each, a 'Relevant State'), no Shares have been offered or will be offered pursuant to the offering to the public in that Relevant State prior to the publication of a prospectus in relation to the Shares which has been approved by the competent authority in that Relevant State or, where appropriate, approved in another Relevant State and notified to the competent authority in that Relevant State, all in accordance with the Prospectus Regulation, except that Shares may be offered to the public in that Relevant State at any time: to any legal entity which is a 'qualified investor' as defined under Article 2 of the Prospectus Regulation; to fewer than 150 natural or legal persons (other than qualified investors as defined under Article 2 of the Prospectus Regulation), subject to obtaining the prior consent of the representatives for any such offer; and in any other circumstances falling within Article 1(4) of the Prospectus Regulation, provided that no such offer of the Shares shall require us or any of the underwriters to publish a prospectus pursuant to Article 3 of the Prospectus Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation. Each person who initially acquires any Shares or to whom any offer is made will be deemed to have represented, warranted, acknowledged and agreed to and with us and each of the underwriters that it is a 'qualified investor' within the meaning of Article 2 of the Prospectus Regulation. For the purposes of the above, the expression 'offer to the public' in relation to the Shares in any Relevant State means the communication in any form and by any means of sufficient information on the terms of the offer and any Shares to be offered so as to enable an investor to decide to purchase or subscribe for any Shares, and the expression 'Prospectus Regulation' means Regulation (EU) 2017/1129. United Kingdom: No Shares have been offered or will be offered pursuant to this offering to the public in the United Kingdom prior to the publication of a prospectus in relation to the Shares which has been approved by the Financial Conduct Authority in the United Kingdom, except that the Shares may be offered to the public in the United Kingdom at any time: a) to any legal entity which is a qualified investor as defined under Article 2 of the UK Prospectus Regulation; b) to fewer than 150 natural or legal persons (other than qualified investors as defined under Article 2 of the UK Prospectus Regulation), subject to obtaining the prior consent of the representatives for any such offer; or c) in any other circumstances falling within Section 86 of the Financial Services and Markets Act 2000 (the 'FSMA'), provided that no such offer of the Shares shall require us or any of the underwriters to publish a prospectus pursuant to Section 85 of the FSMA or Article 3 of the UK Prospectus Regulation or supplement a prospectus pursuant to Article 23 of the UK Prospectus Regulation. Each person in the United Kingdom who initially acquires any Shares or to whom any offer is made will be deemed to have represented, warranted, acknowledged and agreed to and with us and each of the underwriters that it is a 'qualified investor' within the meaning of the UK Prospectus Regulation. For the purposes of this provision, the expression an 'offer to the public' in relation to the Shares in the United Kingdom means the communication in any form and by any means of sufficient information on the terms of the offer and any Shares to be offered so as to enable an investor to decide to purchase or subscribe for any Shares. In addition, in the United Kingdom, the transaction to which this press release relates will only be available to, and will be engaged in only with persons who are 'qualified investors' (as defined in the UK Prospectus Regulation) (i) who have professional experience in matters relating to investments falling within Article 19(5) of the FSMA (Financial Promotion) Order 2005, as amended (the Order), and/or (ii) who are high net worth entities (or persons to whom it may otherwise be lawfully communicated) falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as 'relevant persons'). In the United Kingdom, the securities referred to herein are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in only with relevant persons. Any person in the United Kingdom who is not a relevant person should not act or rely on this communication or any of its contents. About Merus N.V. Merus is an oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation, statements regarding the completion of the proposed offering, the anticipated gross proceeds from the offering and our intended use of any net proceeds from the offering. These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: our need for additional funding, which may not be available and which may require us to restrict our operations or require us to relinquish rights to our technologies or Biclonics®, Triclonics® and multispecific antibody candidates; potential delays in regulatory approval, which would impact our ability to commercialize our product candidates and affect our ability to generate revenue; the lengthy and expensive process of clinical drug development, which has an uncertain outcome; the unpredictable nature of our early stage development efforts for marketable drugs; potential delays in enrollment of patients, which could affect the receipt of necessary regulatory approvals; our reliance on third parties to conduct our clinical trials and the potential for those third parties to not perform satisfactorily; impacts of the global instability caused by the Russia Ukraine conflict and conflict in the Middle East; we may not identify suitable Biclonics® or bispecific antibody candidates under our collaborations or our collaborators may fail to perform adequately under our collaborations; our reliance on third parties to manufacture our product candidates, which may delay, prevent or impair our development and commercialization efforts; protection of our proprietary technology; our patents may be found invalid, unenforceable, circumvented by competitors and our patent applications may be found not to comply with the rules and regulations of patentability; we may fail to prevail in potential lawsuits for infringement of third-party intellectual property; and our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. These and other important factors discussed under the caption 'Risk Factors' in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 filed with the Securities and Exchange Commission, or SEC, on May 7, 2025, and our other reports filed with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change, except as required under applicable law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release. Multiclonics®, ADClonics®, Biclonics® and Triclonics® are registered trademarks of Merus N.V. CONTACT: Investor and Media Inquiries: Sherri Spear Merus N.V. SVP Investor Relations and Strategic Communications 617-821-3246 Kathleen Farren Merus N.V. Director Investor Relations and Corporate Communications 617-230-4165
